Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study

Halil Taskaynatan, Yuksel Kucukzeybek, Yasar Yildiz, Tarik Salman, Utku Oflazoglu, Umut Varol, Ahmet Alacacioglu, Seray Saray, Ozlem Ozdemir, Mustafa Oktay Tarhan.




Abstract
Cited by 0 Articles

Aim: Oral etoposide dosage is roughly 50-100 mg/m2 on days 1 to 21 every 28 days. However, dosage of 50 mg/day oral etoposide for five days a week is not well published. The present study, aimed to evaluate the efficacy and toxicity profile of low dose oral etoposide regimen (50 mg/day on days 1 to 5 every week) in platinum-resistant epithelial ovarian cancer (EOC).
Material and Methods: This study retrospectively evaluates patients with pathologically confirmed platinum-resistant EOC who were unable to tolerate the standard oral etoposide regimen and were on low dose (d1-5/7) oral etoposide regimen in third line or beyond within the period between 2006 and 2014.
Results: The overall response rate among 33 EOC patients was 15.1% while clinical benefit rate was 42.4% (stable disease in 27.3% and partial response in 15.1%). Median progression-free survival was 4 months (95% confidence interval [CI], 2.8–5.1 months) and median overall survival was 12 months (95% CI, 8.8–15.1 months).
Conclusion: We concluded that low dose oral etoposide (50 mg/day, on days 1 to 5 every week) was effective and well tolerated for platinum-resistant EOC.

Key words: Epithelial ovarian cancer; oral etoposide; recurrence






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.